XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2025
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

Three months ended June 30, 

Six months ended June 30, 

2025

    

2024

    

2025

    

2024

External clinical development expenses

$

1,637,683

$

206,277

$

3,334,914

$

763,237

Personnel related and stock-based compensation

 

258,072

 

260,349

 

687,490

 

472,619

Other research and development expenses

 

154,830

 

120,877

 

402,320

 

236,945

Total research and development expenses

$

2,050,585

$

587,503

$

4,424,724

$

1,472,801